Omnix Medical is honored to have earned a recent grant award from the Israel Innovation Authority to support continued development of new and effective lifesaving drugs to combat the spread of antimicrobial resistance.
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials
“Antibacterial agents active against Gram‑Negative Bacilli in Phase I, II, or III Clinical Trials,” by David L. Paterson, surveys nearly 50 investigational therapeutics—28 small‑molecule antibiotics and 21 non‑traditional modalities—now in the clinic. The review highlights
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).